Categories
Remus Pharmaceuticals Limited — Board Meeting, 20-05-2026: Outcome of Board Meeting
20-05-2026 · 03:14 pm
Remus Pharma's board approved strong FY26 consolidated results: Revenue at ₹853.63 Cr & PAT at ₹46.17 Cr. The company's strategic global expansion and B2C growth continue, alongside a proposed dividend of ₹0.50 per share.
No comments yet. Be the first to comment!